2024-11-17 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis Report

**1. Performance vs. S&P 500 (VOO):**

Abbott Laboratories (ABT) is a diversified healthcare company that produces medical devices, pharmaceuticals, and nutritional products.  Over the period analyzed, ABT's cumulative return of 93.93% lagged behind the S&P 500's (VOO) return of 123.86%, resulting in a difference of -29.93%. This places ABT at the 12.29th percentile of its historical performance relative to the S&P 500, based on the provided range of maximum and minimum divergences.

The provided CAGR (Compound Annual Growth Rate) data shows significant variation in ABT's performance over different time periods, ranging from a high of 135.6% to a low of -11.8%.  While Alpha values generally indicate outperformance against the market (values above 1), the recent years show a declining alpha suggesting underperformance relative to the benchmark. The Beta consistently remains around 1, suggesting similar volatility to the broader market.


**2. Recent Price Movement:**

* **Closing Price:** $115.9
* **5-Day Moving Average:** $115.98
* **20-Day Moving Average:** $115.94
* **60-Day Moving Average:** $114.85

The stock price is currently trading slightly below its 5-day and 20-day moving averages, suggesting a minor short-term downward trend. However, it is above its 60-day moving average, indicating a more positive long-term trend.


**3. Technical Indicators and Expected Return:**

* **RSI (Relative Strength Index):** 55.85 – Suggests the stock is neither overbought nor oversold, remaining in a neutral zone.
* **PPO (Percentage Price Oscillator):** -0.15 – A negative value indicates bearish momentum.
* **Recent Relative Divergence:** -4.98 – Shows a recent short-term downward trend in the stock's performance relative to the S&P 500.

The closing price of $115.89 is very close to the moving averages, indicating no significant immediate price movement or substantial divergence from recent trends.  The expected return of 0.0% reflects the difficulty of forecasting long-term outperformance relative to the S&P 500. This projection requires a more sophisticated model that incorporates factors beyond the provided data.

**4. Recent Financial Performance:**

The provided earnings data shows relatively stable revenue, hovering around $10 Billion per quarter. EPS (Earnings Per Share) shows some fluctuations but generally maintains a positive trend.  To adequately assess the most recent results, the expected EPS and revenue for the most recent quarter are needed for comparison and context.


**5.  Financial Information Analysis:**

The provided quarterly data demonstrates consistent revenue and profit margins over the last few quarters with profit margins above 50%. While the equity has experienced growth, ROE (Return on Equity) has shown some fluctuation, indicating changes in the efficiency of capital utilization. More detailed analysis would require examination of the company's balance sheet and cash flow statement, which are not included here.


**6. News and Recent Issues:**

This section requires accessing recent news articles (within the last two days) from sources such as Shacknews and FINBOLD. The report should include any recent earnings announcements, analyst opinions, market outlook, and performance highlights related to ABT.  This information is crucial for a complete and current assessment.


**7. Overall Analysis:**

Abbott Laboratories shows a relatively stable financial position with consistent revenue and profit margins.  However, its recent stock performance has lagged behind the S&P 500. Technical indicators suggest a neutral to slightly bearish short-term outlook, while the long-term outlook is uncertain and depends heavily on future market conditions and company performance.  The addition of news and analyst sentiment in section 6 will be key to a more comprehensive overall assessment.  A thorough due diligence process involving examination of complete financial statements and additional research is recommended before making any investment decisions.


**8.  Disclaimer:**

This report is for informational purposes only and does not constitute investment advice.  The analysis is based solely on the provided data and may not reflect the full complexity of the situation.  Independent research and professional financial advice are strongly recommended before making any investment decisions.
